O	0	8	Efficacy
O	9	12	and
O	13	19	safety
O	20	22	of
B-intervention	23	34	leuprorelin
I-intervention	35	42	acetate
I-intervention	43	44	6
I-intervention	44	45	-
I-intervention	45	50	month
I-intervention	51	56	depot
I-intervention	56	57	,
I-intervention	58	61	TAP
I-intervention	61	62	-
I-intervention	62	65	144
I-intervention	65	66	-
I-intervention	66	68	SR
I-intervention	69	70	(
I-intervention	70	72	6M
I-intervention	72	73	)
I-intervention	73	74	,
I-intervention	75	77	in
I-intervention	78	89	combination
I-intervention	90	94	with
I-intervention	95	104	tamoxifen
O	105	107	in
O	108	121	postoperative
O	121	122	,
O	123	136	premenopausal
O	137	145	patients
O	146	150	with
O	151	158	hormone
O	159	167	receptor
O	167	168	-
O	168	176	positive
O	177	183	breast
O	184	190	cancer
O	190	191	:
O	192	193	a
O	194	199	phase
O	200	203	III
O	203	204	,
O	205	215	randomized
O	215	216	,
O	217	221	open
O	221	222	-
O	222	227	label
O	227	228	,
O	229	237	parallel
O	237	238	-
O	238	243	group
O	244	255	comparative
O	256	261	study
O	261	262	.

O	263	274	Leuprorelin
O	275	282	acetate
O	282	283	,
O	284	285	a
O	286	297	luteinizing
O	298	305	hormone
O	305	306	-
O	306	315	releasing
O	316	323	hormone
O	324	331	agonist
O	331	332	,
O	333	335	is
O	336	340	used
O	341	350	worldwide
O	351	353	in
O	354	367	premenopausal
O	368	373	women
O	374	378	with
O	379	386	hormone
O	387	395	receptor
O	395	396	-
O	396	404	positive
O	405	411	breast
O	412	418	cancer
O	418	419	.

O	420	424	This
O	425	430	study
O	431	434	was
O	435	444	conducted
O	445	447	to
O	448	454	assess
O	455	458	the
O	459	462	non
O	462	463	-
O	463	474	inferiority
O	475	477	of
O	478	481	the
O	482	483	6
O	483	484	-
O	484	489	month
O	490	495	depot
O	496	507	formulation
O	507	508	,
O	509	512	TAP
O	512	513	-
O	513	516	144
O	516	517	-
O	517	519	SR
O	520	521	(
O	521	523	6M
O	523	524	)
O	525	527	22
O	527	528	.
O	528	529	5
O	530	532	mg
O	533	535	to
O	536	539	the
O	540	541	3
O	541	542	-
O	542	547	month
O	548	553	depot
O	554	565	formulation
O	565	566	,
O	567	570	TAP
O	570	571	-
O	571	574	144
O	574	575	-
O	575	577	SR
O	578	579	(
O	579	581	3M
O	581	582	)
O	583	585	11
O	585	586	.
O	586	588	25
O	589	591	mg
O	592	594	in
B-eligibility	595	608	postoperative
I-eligibility	608	609	,
I-eligibility	610	623	premenopausal
I-eligibility	624	632	patients
I-eligibility	633	637	with
I-eligibility	638	645	hormone
I-eligibility	646	654	receptor
I-eligibility	654	655	-
I-eligibility	655	663	positive
I-eligibility	664	670	breast
I-eligibility	671	677	cancer
O	677	678	.

O	679	683	This
O	684	687	was
O	688	689	a
O	690	692	96
O	692	693	-
O	693	697	week
O	698	703	phase
O	704	707	III
O	707	708	,
O	709	719	randomized
O	719	720	,
O	721	725	open
O	725	726	-
O	726	731	label
O	731	732	,
O	733	741	parallel
O	741	742	-
O	742	747	group
O	748	759	comparative
O	760	765	study
O	765	766	.

O	767	770	All
O	771	779	patients
O	780	793	concomitantly
O	794	802	received
O	803	807	oral
O	808	817	tamoxifen
O	818	819	(
O	819	821	20
O	822	824	mg
O	825	830	daily
O	830	831	)
O	831	832	.

O	833	836	The
O	837	844	primary
O	845	853	endpoint
O	854	857	was
O	858	861	the
B-outcome-Measure	862	873	suppression
I-outcome-Measure	874	878	rate
I-outcome-Measure	879	881	of
I-outcome-Measure	882	887	serum
I-outcome-Measure	888	897	estradiol
I-outcome-Measure	898	899	(
I-outcome-Measure	899	901	E2
I-outcome-Measure	901	902	)
O	903	905	to
O	906	909	the
O	910	920	menopausal
O	921	926	level
O	927	928	(
O	928	929	≤
O	929	931	30
O	932	934	pg
O	934	935	/
O	935	937	mL
O	937	938	)
O	939	943	from
O	944	948	Week
O	949	950	4
O	951	958	through
O	959	963	Week
O	964	966	48
O	966	967	.

O	968	970	In
O	971	976	total
O	976	977	,
B-total-participants	978	981	167
O	982	990	patients
O	991	995	were
O	996	1006	randomized
O	1007	1009	to
O	1010	1017	receive
O	1018	1021	TAP
O	1021	1022	-
O	1022	1025	144
O	1025	1026	-
O	1026	1028	SR
O	1029	1030	(
O	1030	1032	6M
O	1032	1033	)
O	1034	1035	(
O	1035	1036	n
O	1037	1038	=
B-intervention-participants	1039	1041	83
O	1041	1042	)
O	1043	1045	or
B-control	1046	1049	TAP
I-control	1049	1050	-
I-control	1050	1053	144
I-control	1053	1054	-
I-control	1054	1056	SR
I-control	1057	1058	(
I-control	1058	1060	3M
I-control	1060	1061	)
O	1062	1063	(
O	1063	1064	n
O	1065	1066	=
B-control-participants	1067	1069	84
O	1069	1070	)
O	1071	1074	and
O	1075	1078	the
B-outcome	1079	1081	E2
I-outcome	1082	1093	suppression
I-outcome	1094	1098	rate
O	1099	1102	was
B-iv-bin-percent	1103	1105	97
I-iv-bin-percent	1105	1106	.
I-iv-bin-percent	1106	1107	6
O	1108	1111	and
B-cv-bin-percent	1112	1114	96
I-cv-bin-percent	1114	1115	.
I-cv-bin-percent	1115	1116	4
I-cv-bin-percent	1117	1118	%
O	1118	1119	,
O	1120	1132	respectively
O	1132	1133	.

O	1134	1137	The
O	1138	1147	estimated
O	1148	1155	between
O	1155	1156	-
O	1156	1161	group
O	1162	1172	difference
O	1173	1176	was
O	1177	1178	1
O	1178	1179	.
O	1179	1180	2
O	1181	1182	%
O	1183	1184	(
O	1184	1186	95
O	1187	1188	%
O	1189	1199	confidence
O	1200	1208	interval
O	1209	1210	-
O	1210	1211	5
O	1211	1212	.
O	1212	1213	2
O	1214	1216	to
O	1217	1218	7
O	1218	1219	.
O	1219	1220	8
O	1220	1221	)
O	1221	1222	.

O	1223	1226	The
O	1227	1230	non
O	1230	1231	-
O	1231	1242	inferiority
O	1243	1245	of
O	1246	1249	TAP
O	1249	1250	-
O	1250	1253	144
O	1253	1254	-
O	1254	1256	SR
O	1257	1258	(
O	1258	1260	6M
O	1260	1261	)
O	1262	1264	to
O	1265	1268	TAP
O	1268	1269	-
O	1269	1272	144
O	1272	1273	-
O	1273	1275	SR
O	1276	1277	(
O	1277	1279	3M
O	1279	1280	)
O	1281	1284	for
O	1285	1287	E2
O	1288	1299	suppression
O	1300	1303	was
O	1304	1313	confirmed
O	1313	1314	.

O	1315	1317	As
O	1318	1321	for
O	1322	1328	safety
O	1328	1329	,
O	1330	1336	common
O	1337	1344	adverse
O	1345	1351	events
O	1352	1356	were
B-outcome	1357	1360	hot
I-outcome	1361	1366	flush
O	1367	1370	and
B-outcome	1371	1380	injection
I-outcome	1381	1385	site
I-outcome	1386	1395	reactions
O	1396	1405	including
O	1406	1416	induration
O	1416	1417	,
B-outcome	1418	1422	pain
O	1422	1423	,
O	1424	1427	and
B-outcome	1428	1436	erythema
O	1437	1439	in
O	1440	1444	both
O	1445	1454	treatment
O	1455	1461	groups
O	1461	1462	,
O	1463	1468	which
O	1469	1473	were
O	1474	1476	of
O	1477	1478	≤
O	1478	1483	Grade
O	1484	1485	2
O	1486	1488	in
O	1489	1497	severity
O	1498	1501	and
O	1502	1505	not
O	1506	1513	serious
O	1513	1514	.

O	1515	1517	No
O	1518	1529	significant
O	1530	1537	between
O	1537	1538	-
O	1538	1543	group
O	1544	1555	differences
O	1556	1558	in
O	1559	1565	safety
O	1566	1574	profiles
O	1575	1578	and
O	1579	1591	tolerability
O	1592	1596	were
O	1597	1605	observed
O	1605	1606	.

O	1607	1610	TAP
O	1610	1611	-
O	1611	1614	144
O	1614	1615	-
O	1615	1617	SR
O	1618	1619	(
O	1619	1621	6M
O	1621	1622	)
O	1623	1626	was
O	1627	1630	not
O	1631	1639	inferior
O	1640	1642	to
O	1643	1646	TAP
O	1646	1647	-
O	1647	1650	144
O	1650	1651	-
O	1651	1653	SR
O	1654	1655	(
O	1655	1657	3M
O	1657	1658	)
O	1659	1662	for
O	1663	1666	its
O	1667	1678	suppressive
O	1679	1685	effect
O	1686	1688	on
O	1689	1694	serum
O	1695	1697	E2
O	1697	1698	.

O	1699	1702	TAP
O	1702	1703	-
O	1703	1706	144
O	1706	1707	-
O	1707	1709	SR
O	1710	1711	(
O	1711	1713	6M
O	1713	1714	)
O	1715	1718	was
O	1719	1723	also
O	1724	1726	as
O	1727	1731	well
O	1732	1741	tolerated
O	1742	1744	as
O	1745	1748	TAP
O	1748	1749	-
O	1749	1752	144
O	1752	1753	-
O	1753	1755	SR
O	1756	1757	(
O	1757	1759	3M
O	1759	1760	)
O	1760	1761	.
